Milestones

Our path so far

  1. 2018

    PyMES Innovadoras grant

    Selected as one of 14 innovative small businesses by the Puerto Rico Industrial Development Company (Government of Puerto Rico).

  2. 2020

    Parallel18 accelerator, Generation 7

    Chosen among the Puerto Rican companies in the 7th generation of the Parallel18 acceleration program.

  3. 2022

    P18 Ventures Business Continuity Fund

    As a Parallel18 Gen. 7 alumnus, Omics received investment from the P18 Ventures Business Continuity Fund, funded by the Puerto Rico Science Trust.

  4. 2022

    Launch in Puerto Rico and the Dominican Republic

    INNOVATIO-ND2 arrives in Puerto Rico, processed by Immuno Reference Lab, and in the Dominican Republic with Macrotech.

  5. 2022

    ISO-certified manufacturing

    Manufacturing of INNOVATIO-ND2 is contracted to Syrviatek Laboratories, an ISO-certified facility.

  6. 2023

    Bravo Family Foundation program

    Omics took part in the entrepreneurship program of the Bravo Family Foundation, Orlando Bravo's foundation, in Mayagüez.

  7. 2024

    Parallel18 XPAND

    Omics took part in Parallel18's XPAND program.

  8. 2024

    Medicare and MCS coverage

    INNOVATIO-ND2 (CPT 0385U) is covered by Traditional Medicare and by MCS, in its Advantage and commercial plans.

  9. 2025

    MMM coverage

    MMM adds coverage in its Advantage and Vital plans.